Cerus Corporation General and Administrative Expenses 2011-2025 | CERS

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Cerus Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
75.9 M	75.5 M	83.3 M	81.3 M	67 M	66.2 M	56.8 M	52.4 M	48.8 M	46 M	37.7 M	30 M	25.7 M	23.1 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
83.3 M	23.1 M	55 M

Quarterly General and Administrative Expenses Cerus Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
18.6 M	21.2 M	20.3 M	17.8 M	19 M	19.8 M	16.2 M	20.5 M	21.6 M	-	19.9 M	19.5 M	20.7 M	-	20.4 M	19.8 M	19.2 M	-	16.3 M	16.1 M	15.9 M	-	16.1 M	16.7 M	16.2 M	-	14 M	14.4 M	13.6 M	-	12.2 M	14.1 M	13.7 M	-	12.2 M	12.4 M	11.7 M	-	10.9 M	12.1 M	11.7 M	-	8.72 M	10.1 M	8.24 M	7.43 M	7.73 M	7.95 M	6.85 M	6.79 M	6.22 M	6.69 M	5.97 M	5.94 M	5.38 M	6.21 M	5.53 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
21.6 M	5.38 M	13.6 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
AbbVie ABBV	14.8 B	$ 223.01	-0.99 %	$ 395 B	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Arbutus Biopharma Corporation ABUS	22.5 M	$ 4.68	1.85 %	$ 777 M	Canada
Aclaris Therapeutics ACRS	22.2 M	$ 3.38	3.21 %	$ 261 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	73.5 M	-	-15.15 %	$ 60.3 M	Britain
Aeglea BioTherapeutics AGLE	45.8 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	160 M	$ 212.3	5.5 %	$ 5 B	Danmark
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
BioVie BIVI	8.57 M	$ 1.54	-2.53 %	$ 2.28 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Aptorum Group Limited APM	5.41 M	$ 1.33	-1.48 %	$ 7.25 M	China
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.4	1.49 %	$ 8.18 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	15.2 B	$ 90.34	-1.28 %	$ 96.9 B	Britain
Amphastar Pharmaceuticals AMPH	56.7 M	$ 25.76	0.19 %	$ 1.25 B	USA
Anika Therapeutics ANIK	95.8 M	$ 9.53	-1.19 %	$ 140 M	USA
Aytu BioScience AYTU	17.4 M	$ 2.33	2.3 %	$ 14.6 M	USA
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Axon Enterprise AXON	741 M	$ 586.28	3.15 %	$ 44.4 B	USA
Biogen BIIB	2.4 B	$ 173.03	-2.55 %	$ 25.2 B	USA
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 0.29	-5.01 %	$ 631 M	Israel
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
Benitec Biopharma BNTC	6.97 M	$ 12.91	0.78 %	$ 531 M	USA
BioNTech SE BNTX	286 M	$ 95.9	0.17 %	$ 27.2 B	Germany
Biohaven Pharmaceutical Holding Company Ltd. BHVN	714 M	$ 11.55	8.86 %	$ 747 M	USA
Enochian Biosciences ENOB	17.9 M	-	-	$ 40.5 M	USA
Catalyst Biosciences CBIO	14.7 M	$ 15.32	5.73 %	$ 1.01 B	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Burford Capital Limited BUR	99.3 M	$ 9.15	-0.44 %	$ 1.47 B	Britain
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	166 M	-	-	$ 546 M	USA
Cellectar Biosciences CLRB	11.7 M	$ 3.81	-5.35 %	$ 46.6 M	USA
Bristol-Myers Squibb Company BMY	8.41 B	$ 51.05	-0.32 %	$ 103 B	USA
Abeona Therapeutics ABEO	19 M	$ 5.5	0.46 %	$ 118 M	USA
ADiTx Therapeutics ADTX	16.3 M	$ 2.36	-7.29 %	$ 31.1 K	USA
BioXcel Therapeutics BTAI	34.5 M	$ 2.1	-4.34 %	$ 5.32 M	USA
Coherus BioSciences CHRS	192 M	$ 1.42	6.77 %	$ 134 M	USA
BioLineRx Ltd. BLRX	4.31 M	$ 3.22	-2.72 %	$ 908 M	Israel
Celldex Therapeutics CLDX	38.5 M	$ 28.33	0.5 %	$ 1.82 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Baudax Bio BXRX	24.1 M	-	0.59 %	$ 63 K	USA
Завод ДИОД DIOD	19.7 M	-	-	-	Russia